Label: XIIDRA- lifitegrast solution/ drops

  • NDC Code(s): 0078-0911-05, 0078-0911-12, 0078-0911-94, 0078-0911-95
  • Packager: Novartis Pharmaceuticals Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated August 2, 2023

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use XIIDRA safely and effectively. See full prescribing information for XIIDRA. XIIDRA® (lifitegrast ophthalmic solution), for topical ...
  • Table of Contents
    Table of Contents
  • 1     INDICATIONS AND USAGE
    Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
  • 2     DOSAGE AND ADMINISTRATION
    Instill one drop of Xiidra twice daily (approximately 12 hours apart) into each eye using a single-use container. Discard the single-use container immediately after using in each eye. Contact ...
  • 3     DOSAGE FORMS AND STRENGTHS
    Ophthalmic solution containing lifitegrast 50 mg/mL (5%).
  • 4     CONTRAINDICATIONS
    Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation [see Adverse Reactions (6.2)].
  • 6     ADVERSE REACTIONS
    The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4)] 6.1     Clinical Trials Experience - Because clinical trials are ...
  • 8     USE IN SPECIFIC POPULATIONS
    8.1     Pregnancy - Risk Summary - There are no available data on Xiidra use in pregnant women to inform any drug-associated risks. Intravenous (IV) administration of lifitegrast to pregnant ...
  • 11     DESCRIPTION
    The chemical name for lifitegrast is (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid. The molecular formula ...
  • 12     CLINICAL PHARMACOLOGY
    12.1     Mechanism of Action - Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular ...
  • 13     NONCLINICAL TOXICOLOGY
    13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility - Carcinogenesis - Animal studies have not been conducted to determine the carcinogenic potential of ...
  • 14     CLINICAL STUDIES
    The safety and efficacy of lifitegrast for the treatment of DED were assessed in a total of 1181 patients (1067 of which received lifitegrast 5%) in four 12-week, randomized, multi-center ...
  • 16     HOW SUPPLIED/STORAGE AND HANDLING
    Xiidra (lifitegrast ophthalmic solution) 5% (50 mg/mL) is supplied in a foil pouch containing 5 low-density polyethylene 0.2 mL single-use containers. Carton of 60 single-use ...
  • 17     PATIENT COUNSELING INFORMATION
    Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Handling the Single-use Container - Advise patients not to touch the tip of the single-use ...
  • PATIENT PACKAGE INSERT
    This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: June 2020 - PATIENT INFORMATION - XIIDRA® (ZYE-druh) (lifitegrast ophthalmic solution ...
  • INSTRUCTIONS FOR USE
    This Instructions for Use has been approved by the U.S. Food and Drug Administration.Revised: June 2020 - INSTRUCTIONS FOR USE - XIIDRA® [ZYE-druh] (lifitegrast ophthalmic ...
  • PRINCIPAL DISPLAY PANEL
    NDC 0078-0911-12 - Rx Only - 60 Single-Use - Containers: 12 pouches x 5 single-use - containers (0.2 mL each) xiidra® (lifitegrast - ophthalmic solution) 5% NOVARTIS
  • INGREDIENTS AND APPEARANCE
    Product Information